Keywords: pharma, hit, german, health, reforms, bite, otc
Pharma hit as German health reforms bite, but OTC industry sees "evasive action"
Article | 14 June 2004
Germany's drugs market contracted markedly in first-quarter 2004, under the influence of the government health service reforms, with the 12 leading makers ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
